Cargando…
Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients
Necroptosis plays a major role in breast cancer (BC) progression and metastasis. Besides, necroptosis also regulates inflammatory response and tumor microenvironment. Here, we aim to explore the predictive signature based on necroptosis-related genes (NRGs) for predicting the prognosis and response...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306193/ https://www.ncbi.nlm.nih.gov/pubmed/35864548 http://dx.doi.org/10.1186/s12967-022-03535-z |
_version_ | 1784752493340655616 |
---|---|
author | Yu, Honghao Lv, Wenchang Tan, Yufang He, Xiao Wu, Yiping Wu, Min Zhang, Qi |
author_facet | Yu, Honghao Lv, Wenchang Tan, Yufang He, Xiao Wu, Yiping Wu, Min Zhang, Qi |
author_sort | Yu, Honghao |
collection | PubMed |
description | Necroptosis plays a major role in breast cancer (BC) progression and metastasis. Besides, necroptosis also regulates inflammatory response and tumor microenvironment. Here, we aim to explore the predictive signature based on necroptosis-related genes (NRGs) for predicting the prognosis and response to therapies. Using Lasso multivariate cox analysis, we firstly established the NRG signature based on TCGA database. A total of 6 NRGs (FASLG, IPMK, FLT3, SLC39A7, HSP90AA1, and LEF1), which were associated with the prognosis of BC patients, were selected to establish our signature. Next, CIBERSORT algorithm was utilized to evaluate immune cell infiltration levels. We compare the response to immunotherapy using IMvigor 210 database, and also compared immune indicators in two risk groups via multiple methods. The biological function of IPMK was explored via in vitro verification. Finally, our results indicated that the signature was an independent prognostic indicator for BC patients with better efficiency than other reported signatures. The immune cell infiltration levels were higher, and the response to immunotherapy and chemotherapy was better in the low-risk groups. Besides, other immunotherapy-related factors, including TMB, TIDE, and expression of immune checkpoints were also increased in the low-risk group. Clinical sample validation showed that CD206 and IPMK in clinical samples were both up-regulated in the high-risk group. In vitro assay showed that IPMK promoted BC cell proliferation and migration, and also enhanced macrophage infiltration and M2 polarization. In summary, we successfully established the NRG signature, which could be used to evaluate BC prognosis and identify patients who will benefit from immunotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03535-z. |
format | Online Article Text |
id | pubmed-9306193 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-93061932022-07-23 Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients Yu, Honghao Lv, Wenchang Tan, Yufang He, Xiao Wu, Yiping Wu, Min Zhang, Qi J Transl Med Research Necroptosis plays a major role in breast cancer (BC) progression and metastasis. Besides, necroptosis also regulates inflammatory response and tumor microenvironment. Here, we aim to explore the predictive signature based on necroptosis-related genes (NRGs) for predicting the prognosis and response to therapies. Using Lasso multivariate cox analysis, we firstly established the NRG signature based on TCGA database. A total of 6 NRGs (FASLG, IPMK, FLT3, SLC39A7, HSP90AA1, and LEF1), which were associated with the prognosis of BC patients, were selected to establish our signature. Next, CIBERSORT algorithm was utilized to evaluate immune cell infiltration levels. We compare the response to immunotherapy using IMvigor 210 database, and also compared immune indicators in two risk groups via multiple methods. The biological function of IPMK was explored via in vitro verification. Finally, our results indicated that the signature was an independent prognostic indicator for BC patients with better efficiency than other reported signatures. The immune cell infiltration levels were higher, and the response to immunotherapy and chemotherapy was better in the low-risk groups. Besides, other immunotherapy-related factors, including TMB, TIDE, and expression of immune checkpoints were also increased in the low-risk group. Clinical sample validation showed that CD206 and IPMK in clinical samples were both up-regulated in the high-risk group. In vitro assay showed that IPMK promoted BC cell proliferation and migration, and also enhanced macrophage infiltration and M2 polarization. In summary, we successfully established the NRG signature, which could be used to evaluate BC prognosis and identify patients who will benefit from immunotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03535-z. BioMed Central 2022-07-21 /pmc/articles/PMC9306193/ /pubmed/35864548 http://dx.doi.org/10.1186/s12967-022-03535-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Yu, Honghao Lv, Wenchang Tan, Yufang He, Xiao Wu, Yiping Wu, Min Zhang, Qi Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients |
title | Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients |
title_full | Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients |
title_fullStr | Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients |
title_full_unstemmed | Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients |
title_short | Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients |
title_sort | immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306193/ https://www.ncbi.nlm.nih.gov/pubmed/35864548 http://dx.doi.org/10.1186/s12967-022-03535-z |
work_keys_str_mv | AT yuhonghao immunotherapylandscapeanalysesofnecroptosischaracteristicsforbreastcancerpatients AT lvwenchang immunotherapylandscapeanalysesofnecroptosischaracteristicsforbreastcancerpatients AT tanyufang immunotherapylandscapeanalysesofnecroptosischaracteristicsforbreastcancerpatients AT hexiao immunotherapylandscapeanalysesofnecroptosischaracteristicsforbreastcancerpatients AT wuyiping immunotherapylandscapeanalysesofnecroptosischaracteristicsforbreastcancerpatients AT wumin immunotherapylandscapeanalysesofnecroptosischaracteristicsforbreastcancerpatients AT zhangqi immunotherapylandscapeanalysesofnecroptosischaracteristicsforbreastcancerpatients |